202 related articles for article (PubMed ID: 28302042)
1. Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
Marasini B; Sahu RP
Mini Rev Med Chem; 2017; 17(11):920-927. PubMed ID: 28302042
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.
Hosseini M; Hassanian SM; Mohammadzadeh E; ShahidSales S; Maftouh M; Fayazbakhsh H; Khazaei M; Avan A
J Cell Biochem; 2017 Jul; 118(7):1634-1638. PubMed ID: 28106283
[TBL] [Abstract][Full Text] [Related]
3. Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.
Yue Q; Gao G; Zou G; Yu H; Zheng X
Biomed Res Int; 2017; 2017():8412508. PubMed ID: 28232946
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
5. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Kanai M; Yoshimura K; Asada M; Imaizumi A; Suzuki C; Matsumoto S; Nishimura T; Mori Y; Masui T; Kawaguchi Y; Yanagihara K; Yazumi S; Chiba T; Guha S; Aggarwal BB
Cancer Chemother Pharmacol; 2011 Jul; 68(1):157-64. PubMed ID: 20859741
[TBL] [Abstract][Full Text] [Related]
7. [The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
Mohelníková-Duchonová B; Soucek P
Klin Onkol; 2010; 23(5):306-10. PubMed ID: 21061681
[TBL] [Abstract][Full Text] [Related]
8. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.
Murugesan SR; King CR; Osborn R; Fairweather WR; O'Reilly EM; Thornton MO; Wei LL
Cancer Gene Ther; 2009 Nov; 16(11):841-7. PubMed ID: 19444305
[TBL] [Abstract][Full Text] [Related]
9. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer.
Khan S; Setua S; Kumari S; Dan N; Massey A; Hafeez BB; Yallapu MM; Stiles ZE; Alabkaa A; Yue J; Ganju A; Behrman S; Jaggi M; Chauhan SC
Biomaterials; 2019 Jul; 208():83-97. PubMed ID: 30999154
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
12. [Second line chemotherapy for pancreatic cancer].
Park JY
Korean J Gastroenterol; 2011 Apr; 57(4):207-12. PubMed ID: 21519173
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Banerjee S; Choi M; Aboukameel A; Wang Z; Mohammad M; Chen J; Yang D; Sarkar FH; Mohammad RM
Pancreas; 2010 Apr; 39(3):323-31. PubMed ID: 19823097
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
Büchler P; Reber HA; Eibl G; Roth MA; Büchler MW; Friess H; Isacoff WH; Hines OJ
Int J Oncol; 2005 Oct; 27(4):1125-30. PubMed ID: 16142331
[TBL] [Abstract][Full Text] [Related]
15. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
Banerjee S; Kaseb AO; Wang Z; Kong D; Mohammad M; Padhye S; Sarkar FH; Mohammad RM
Cancer Res; 2009 Jul; 69(13):5575-83. PubMed ID: 19549912
[TBL] [Abstract][Full Text] [Related]
17. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
Mamaghani S; Patel S; Hedley DW
BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Cereda S; Reni M
J Chemother; 2008 Aug; 20(4):509-12. PubMed ID: 18676234
[TBL] [Abstract][Full Text] [Related]
20. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Tu C; Zheng F; Wang JY; Li YY; Qian KQ
Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
